Literature DB >> 9872338

Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat.

Y Wang1, R Aun, F L Tse.   

Abstract

This study was conducted to determine the uptake of dihydroergotamine (DHE) into the brain after intravenous and intranasal administration in rats. Eight anesthetized rats received either an intravenous (i.v.) or two successive intranasal (i.n.) doses of tritium labeled dihydroergotamine (3H-DHE) with 14C-inulin as a non-BBB (blood-brain barrier) permeable marker. Radioactivity concentrations in plasma were determined at designated times within 30 min postdose, and in blood and seven brain regions (olfactory bulb, frontal cortex, parietal cortex, occipital cortex, cerebellum, mid-brain areas, and brain stem) at 30 min. The plasma-to-brain permeability*area product (PeA) following an i.v. dose was calculated based on the 30-min brain tissue concentration and the area under the plasma concentration-time curve (AUC0-30 min, i.v.) assuming unidirectional transport from plasma to brain. Direct transport from nasal cavity to brain was assessed based on the amount of radioactivity in brain determined experimentally and predicted based on plasma AUC0-30 min, i.n. and PeA obtained from i.v. data. Following an i.v. dose, DHE distributed into the brain with a brain-to-plasma concentration ratio of approximately 5% at 30 min postdose. The PeA value of DHE ranged from 8.6 x 10(-4) to 37.5 x 10(-4) mL min(-1) g(-1) in different brain regions. Following i.n. doses the experimentally determined concentration in olfactory bulb was approximately 51 times, and in other regions three to seven times, greater than predicted values based only on PeA and plasma AUC, suggesting a direct transport pathway from the nasal cavity to the brain. As a result, the brain tissue concentrations at 30 min were similar to (0.31-1.04 times) those following an i.v. dose except for the olfactory bulb, in which the concentration was approximately four times greater than that following an i.v. dose. In conclusion, 3H-DHE penetrated the BBB following intravenous administration. Following i.n. doses, 3H-DHE was able to enter the brain directly from the nasal cavity, with the olfactory bulb being a part of the direct passage from nasal cavity to brain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9872338     DOI: 10.1002/(sici)1099-081x(199812)19:9<571::aid-bdd142>3.0.co;2-o

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  13 in total

1.  Nose-to-brain transport pathways of wheat germ agglutinin conjugated PEG-PLA nanoparticles.

Authors:  Qingfeng Liu; Yehong Shen; Jie Chen; Xiaoling Gao; Chengcheng Feng; Lu Wang; Qizhi Zhang; Xinguo Jiang
Journal:  Pharm Res       Date:  2011-12-14       Impact factor: 4.200

2.  Transfer of dopamine in the olfactory pathway following nasal administration in mice.

Authors:  M Dahlin; U Bergman; B Jansson; E Björk; E Brittebo
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

3.  Biovector nanoparticles improve antinociceptive efficacy of nasal morphine.

Authors:  D Betbeder; S Spérandio; J P Latapie; J de Nadai; A Etienne; J M Zajac; B Francés
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

4.  Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats.

Authors:  R Jayachandra Babu; Pankaj Patrick Dayal; Kasturi Pawar; Mandip Singh
Journal:  J Drug Target       Date:  2011-03-23       Impact factor: 5.121

5.  Pharmacokinetics of substrate uptake and distribution in murine brain after nasal instillation.

Authors:  Candace L Graff; Rong Zhao; Gary M Pollack
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

Review 6.  Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS.

Authors:  Anupam Sarma; Malay K Das
Journal:  Mol Biomed       Date:  2020-12-10

7.  Direct nose-to-brain transfer of morphine after nasal administration to rats.

Authors:  Ulrika Espefält Westin; Emma Boström; Johan Gråsjö; Margareta Hammarlund-Udenaes; Erik Björk
Journal:  Pharm Res       Date:  2006-02-25       Impact factor: 4.200

Review 8.  Clinical pharmacokinetics of intranasal sumatriptan.

Authors:  Eliane Fuseau; Olivier Petricoul; Katy H P Moore; Andrew Barrow; Tim Ibbotson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  In situ and in vivo study of nasal absorption of paeonol in rats.

Authors:  Xiaolan Chen; Yang Lu; Shouying Du; Bing Xu; Shan Wang; Yongsong Zhai; Xiao Song; Pengyue Li
Journal:  Int J Mol Sci       Date:  2010-11-26       Impact factor: 5.923

Review 10.  Intranasal administration of acetylcholinesterase inhibitors.

Authors:  Henry R Costantino; Alexis Kays Leonard; Gordon Brandt; Paul H Johnson; Steven C Quay
Journal:  BMC Neurosci       Date:  2008-12-10       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.